title: Safety of long-acting beta-agonists: urgent need to clear the air remains.
authors.forename: R
authors.initials: R
authors.lastname: Beasley
authors.forename: F D
authors.initials: FD
authors.lastname: Martinez
authors.forename: A
authors.initials: A
authors.lastname: Hackshaw
authors.forename: K F
authors.initials: KF
authors.lastname: Rabe
authors.forename: P J
authors.initials: PJ
authors.lastname: Sterk
authors.forename: R
authors.initials: R
authors.lastname: Djukanovic
mesh_terms: D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000009:adverse effects*; D000420:Albuterol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D001249:Asthma / Q000188:drug therapy* / Q000401:mortality*; D004983:Ethanolamines / Q000008:administration & dosage / Q000009:adverse effects*; D000068759:Formoterol Fumarate; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D000068299:Salmeterol Xinafoate
chemical_list: D000318:Adrenergic beta-Agonists; D004983:Ethanolamines; D005938:Glucocorticoids; D000068299:Salmeterol Xinafoate; D000420:Albuterol; D000068759:Formoterol Fumarate